United States

Back to map

Showing 221-230 of 353 grants

Title Institution Researcher Program Duration Total Award Amount
Local delivery of immunomodulators to enable systemic immunosuppression-free efficient islet transplantation The Regents of the University of California, San Francisco Bhushan Kharbikar Cures 01-March-2024 to 28-February-2027 $215,604.64
Targeting Complement-Driven Antigen Presentation in Tertiary Lymphoid Structures to Prevent Type 1 Diabetes The Regents of the University of California, San Francisco Anil Bhushan Cures 01-September-2026 to 31-August-2028 $498,142.00
Triple therapy for T1DM with insulin, semaglutide and dapagliflozin The Research Foundation of SUNY on behalf of University at Buffalo Paresh Dandona Improving Lives 01-January-2019 to 31-December-2026 $1,808,522.70
Project Tuyinza The Sonia Nabeta Foundation Vivian Nabeta Mission 01-April-2026 to 31-March-2029 $643,550.00
Quality, Equity & Outcomes Program The Sonia Nabeta Foundation Vivian Nabeta Mission 01-September-2026 to 31-August-2028 $1,400,000.00
Engineered Nanoparticles for Beta Cell-Targeted Therapeutics The University of Chicago Raghavendra Mirmira Cures 01-April-2023 to 31-August-2026 $897,822.00
Expanding the Therapeutic and Targeting Capacity of Lipid Nanoparticles for Beta-Cell Protection The University of Chicago Raghavendra Mirmira Cures 01-September-2026 to 31-August-2028 $471,201.00
A pilot study assessing the safety of using a monoclonal antibody against CD40 ligand to achieve a calcineurin inhibitor-free immunosuppression regimen in patients with type 1 diabetes mellitus (T1D) and problematic hypoglycemia undergoing islet cell transplantation The University of Chicago Piotr Witkowski Cures 01-February-2024 to 31-October-2026 $250,000.00
A pilot study assessing the safety of using a monoclonal antibody against CD40 ligand to achieve a calcineurin inhibitor-free immunosuppression regimen in patients with type 1 diabetes mellitus (T1D) and problematic hypoglycemia undergoing islet cell transplantation The University of Chicago Piotr Witkowski Cures 01-February-2025 to 31-January-2027 $1,500,000.00
Safety and efficacy assessment of Tegoprubart and calcineurin inhibitors- free immunosuppression therapy for pancreatic islet transplantation in patients with t1DM and chronic kidney disease. The University of Chicago Piotr Witkowski Cures 01-September-2025 to 31-August-2029 $8,500,000.00